Lantern Pharma's AI-Driven Cancer Drug Shows Promise in Phase 1 Trial

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and genomics to revolutionize oncology drug development, has reported promising clinical insights from its completed Phase 1a dose-escalation study of LP-184. The study, involving 63 heavily pre-treated patients with advanced solid tumors, successfully met all primary safety and tolerability endpoints and established a clear recommended Phase 2 dose. Encouragingly, the trial observed durable disease control signals, particularly in tumors with DNA damage repair pathway deficiencies, highlighting LP-184's potential in targeting specific genetic vulnerabilities. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across aggressive cancers including triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma. The company and independent analysts estimate LP-184's aggregate market opportunity could exceed $10 billion annually, reflecting the significant unmet need in these challenging oncology areas.

The company's proprietary AI and machine learning platform, RADR®, which leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms, has been instrumental in accelerating the development of their growing pipeline. This AI-driven approach helps solve billion-dollar problems in oncology drug development by identifying promising candidates and optimizing clinical trial design. Lantern's innovative product candidates, which span both solid tumors and blood cancers including an antibody-drug conjugate program, are estimated to have a combined annual market potential of over $15 billion. The company's newsroom at https://ibn.fm/LTRN provides the latest updates, while the full press release can be accessed at https://ibn.fm/7d7md for those seeking comprehensive details about these developments.

This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on biotechnology and life sciences sectors. BioMedWire provides enhanced press release distribution, article syndication to 5,000+ outlets, and social media distribution via IBN to millions of followers, ensuring maximum visibility for important medical breakthroughs. The platform's comprehensive corporate communications solutions help companies like Lantern Pharma reach investors, influencers, journalists, and the general public effectively. For more information about BioMedWire's services, visit https://www.BioMedWire.com, where breaking news, insightful content, and actionable information converge to bring clients unparalleled recognition and brand awareness in the competitive biotech landscape.